Clinical Trial Update: Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating safety and impact of SelG1 with or without hydroxyurea in sickle cell disease patients experiencing pain crises has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Sickle Cell Disease

Drugs mentioned

• HYDROXYUREA (Hydroxyurea)
• SelG1 (SelG1)

Snippet

Sponsor: Reprixys Pharmaceutical Corporation | Conditions: Sickle Cell Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-01-31